Protara Therapeutics, Inc. · NASDAQ:TARA
Protara Therapeutics — Society of Urologic Oncology Annual Meeting December 2025
20 slides from Protara Therapeutics's conference presentation, Dec 3, 2025
Slide 1: Interim Data Presentation From the ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
Interim Data Presentation From the ADVANCED - 2 Trial of TARA - 002 in BCG - Naïve NMIBC Patients Society Of Urologic Oncology Annual Meeting December 2025
Slide 2: Forward-looking statements
2 Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" wi thi n the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes, ” “ potential,” “proposed,”
Slide 3: Agenda
Jesse Shefferman Co - founder, Director, Chief Executive Officer Jacqueline Zummo, PhD Co - founder, Senior Vice President, Chief Scientific Operations Officer Neal Shore, MD Medical Director, Carolina Urologic Research Center Introduction and TARA - 002 Overview Jesse Shefferman Review of Updated D
Slide 4: Key Clinical and Regulatory Updates in NMIBC
Key Clinical and Regulatory Updates 4 TARA - 002 in NMIBC 1. Updated interim data from the Phase 2 ADVANCED - 2 trial of TARA - 002 in BCG - Naïve NMIBC patients • TARA - 002 demonstrated 72% CR rate at any time, 69% 6 - month landmark CR rate and 50% 12 - month landmark CR rate 1 • Favorable safety
Slide 5: Pipeline
*Currently in pre - clinical studies to define dosing and, once protocol is confirmed, expect to initiate P2 trial cohort. **IV Choline granted Orphan Drug Designations by the U.S. FDA for the prevention and/or treatment of choline deficiency in pa ti ents on long - term PN and Fast Track Designatio
Slide 6: Lyophilized, Inactivated Group A Streptococcus pyogenes
TARA - 002 Lyophilized, Inactivated Group A Streptococcus pyogenes
Slide 7: A Unique TLR2/NOD2 Agonist Derived From Streptococcus Pyogenes
TARA - 002 ignites both innate and adaptive immunity through dual TLR2/NOD2 activation, driving potent local anti - tumor / cystic responses via fully inactivated bacteria (1)(2)(3) © 2025 Protara Therapeutics. All Rights Reserved – Do Not Copy or Distribute. | 7 1 Fujimoto T., et al. J Immunol. 199
Slide 8: Potent Immune Activation with a Distinct Cytokine Signature
Cytokines BCG TARA - 002 IFN - γ --- + TNF - α + +++ IL - 12p70 = + IL - 8 = - IL - 6 + + IL - 1β +++ +++ IL - 10 = + IL - 4 + + IL - 13 = = IL - 2 -- -- TARA - 002 DEMONSTRATES DIFFERENTIATED PROFILE TO BCG © 2025 Protara Therapeutics. All Rights Reserved – Do Not Copy or Distribute. | 8 = : No cha
Slide 9: ADVANCED-2 Results in BCG-Naïve Patients
ADVANCED - 2 RESULTS IN BCG - NAÏVE PATIENTS SUO Poster Presentation © 2025 Protara Therapeutics. All Rights Reserved – Do Not Copy or Distribute.
Slide 10: ADVANCED-2 Clinical Trial Design in NMIBC
Abbreviations: CR = complete response; CIS = carcinoma in situ *Aligned with the FDA’s 2024 BCG Unresponsive NMIBC: Developing Drugs and Biologics for Treatment Guidance for Industry. **Enrollment complete †Residual CIS and/or recurrence of HGTa; ^3 weekly instillations every 3 months through month
Slide 11: Monotherapy Demonstrates 69% CR at 6 Months and 50% CR at 12 Months in BCG-Naïve Participants
TARA - 002 Monotherapy Demonstrates 69% CR at 6 months and 50% CR at 12 Months in BCG - Naïve Participants 11 Abbreviations: CR = complete response High - grade CR is based on central pathology. Notes: Evaluable participants include those who had at least one dose of study drug before the response a
Slide 12: Favorable Safety and Tolerability Profile with No Grade 3 or Greater TRAEs
N = 31 Any Grade Grade 1 Grade 2 Grade 3 Grade 4/5 TRAEs, n (%) 8 (26) 8 (26) 1 (3) 0 0 TRAEs ≥5%, n (%) 17 (55) 15 (48) 2 (6) 0 0 Dysuria 4 (13) 4 (13) 0 0 0 Fatigue 4 (13) 3 (10) 1 (3) 0 0 Haematuria 2 (6) 2 (6) 0 0 0 SAEs, n (%) 4 (13) 0 1 (3) 4 (13) 0 Related SAEs, n (%) 0 0 0 0 0 TRAEs leading
Slide 13: Target Product Profile Fits at the Intersection that NMIBC Patients and Urologists Prioritize
13 TARA - 002 Target Product Profile Fits at the Intersection that NMIBC Patients and Urologists Prioritize © 2025 Protara Therapeutics. All Rights Reserved – Do Not Copy or Distribute. | Safety & Tolerability Efficacy and Durability Ease - of - Use • Mild, self - limited local AEs • Predictable, we
Slide 14: KOL Discussion
KOL DISCUSSION Neal Shore, MD Medical Director, Carolina Urologic Research Center
Slide 15: FDA Aligned with Us On Our Proposed BCG-Naïve Definition and Design
FDA Aligned with Us On Our Proposed BCG - Naïve Definition and Design 15 Reached alignment on Under discussion No BCG in comparator arm Definition of BCG - Naïve study population (never been exposed and those who have not received BCG within the last 24 - months and who are ineligible to receive BCG
Slide 16: Closing Remarks
CLOSING REMARKS 16
Slide 17: Q&A
Q&A Jesse Shefferman Co - founder, Director, Chief Executive Officer Jacqueline Zummo, PhD Co - founder, Senior Vice President, Chief Scientific Operations Officer Neal Shore, MD Medical Director, Carolina Urologic Research Center © 2025 Protara Therapeutics. All Rights Reserved – Do Not Copy or Dis
Slide 18: Thank You
THANK YOU CU] vs ROTARA THERAPEUTICS
Slide 19: Appendix
SSARSSSOGG ——-— - IAG SSS SSA SS SR S ae SAAN APPENDIX
Slide 20: Demographics and Baseline Characteristics in BCG-Naïve Participants
Demographics Cohort A N = 31 Baseline Characteristics Cohort A N = 31 Age (years) ECOG PS, n (%) Mean (SD) 70.4 (10.29) 0 26/31 (83.9) Median (Min, Max) 71 (45, 89) 1 4/31 (12.9) Sex, n (%) 2 1/31 (3.2) Male 25/31 (80.6) 3 0 Female 6/31 (19.4) 4 0 Race, n (%) 5 0 American Indian or Alaska Native 0 D
Protara Therapeutics — Society of Urologic Oncology Annual Meeting December 2025 on 6ix